Researchers from North Carolina State University have synthesized an analog of lipoxazolidinone A, a small molecule that is effective against drug-resistant bacteria such as MRSA. This molecule, a new synthetic compound inspired by a natural product, could be a useful chemical tool for studying other Gram-positive infections and may have implications for future drug creation.
Lipoxazolidinone A is a natural product which had been previously isolated from bacteria living in marine sediments. It is a secondary metabolite – a small molecule produced by the bacteria that isn’t key to its survival but is produced for a secondary purpose, like defense. When lipoxazolidinone A was initially isolated, researchers noted that it seemed effective against Gram-positive bacteria, like MRSA.
NC State chemist Joshua Pierce aimed to confirm those original findings and understand how the molecule’s structure correlated to its function; in short, he wanted to recreate the molecule to see what portions were directly responsible for its anti-microbial properties and then potentially improve upon that structure.
Pierce, along with current NC State graduate student Kaylib Robinson and former students Jonathan Mills and Troy Zehnder, used novel chemical tools to synthesize lipoxazolidinone A in the lab. They were able to confirm that its chemical structure matched what the initial researchers had indicated, then they worked to identify the portion of the molecule that was responsible for the activity against Gram-positive bacteria. Their result was a compound with improved potency, JJM-35.
They tested JJM-35 against a panel of resistant and non-resistant bacteria. When tested against MRSA in vitro, they found that the synthesized molecule was up to 50 times more effective than the natural product against several bacterial strains. Additionally, they found that the molecule was often more effective against resistant bacterial strains than it was against nonresistant strains.
“An exciting additional aspect of this work was that we identified that these molecules may function by inhibiting multiple biosynthetic pathways directly or indirectly,” says Pierce. “This means that bacteria may have difficulty developing resistance to potential drugs developed from these molecules.”
While more work is needed, Pierce hopes that JJM-35 and similar compounds can be used as tools to study other Gram-positive bacteria and provide a platform for the development of a novel class of anti-infective agents.
“At this point, we have a chemical scaffold – a starting piece of the puzzle. We know that this piece is effective, and so right now all efforts are focused on evaluating the properties of these molecules and their in vivo efficacy,” says Pierce. “The hope is that we can build upon this scaffold to create drugs that are effective against MRSA and other resistant bacteria at a time of dire need for antimicrobial development while also increasing the spectrum of activity.”
The Latest on: Antimicrobial development
via Google News
The Latest on: Antimicrobial development
Antimicrobial Additives Market Analysis by 2025: Top Players Like DOW Chemical, BASF, BioCote, Clariant, RTP, A. Schulman
on August 14, 2018 at 8:17 pm
The industry experts have left no stone unturned to identify the major factors influencing the development rate of the Antimicrobial Additives industry including various opportunities and gaps. A thor... […]
ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections
on August 14, 2018 at 2:00 pm
Dr. Cassino will provide industry perspective on the development of lysin therapeutics to treat ... An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections ... […]
Contrafect Corporation: A Novel Antimicrobial Technology To Combat Hospital Acquired Infections
on August 13, 2018 at 12:40 pm
Contrafect published this past year in the journal of antimicrobial agents and chemotherapy on the ... Also, more than likely CF-301 would have to undergo some further development and optimization in ... […]
N8 Medical Announces NHLBI Grant to Develop Antimicrobial Pacemaker Envelope
on August 7, 2018 at 11:30 am
N8 Medical is enthusiastic about the further development and validation of its breakthrough ... http://www.prnewswire.com/news-releases/n8-medical-announces-nhlbi-grant-to-develop-antimicrobial-pacema... […]
FDA pushes for better antimicrobial stewardship in veterinary medicine
on August 1, 2018 at 12:22 pm
However, we know that overuse or misuse of these drugs promotes the development of antimicrobial-resistant bacteria.” For those reasons, the FDA is asking that good practices be implemented in both hu... […]
National Research : Design Development and Maintenance Work of Antimicrobial Agent Usage Amount Compilation System
on July 30, 2018 at 4:37 am
Address : 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655 National Research and Development Corporation National International Medical Research Center General Affairs Department General Affairs Division Pro... […]
Herbal drug to prevent antimicrobial resistance in cattle
on July 30, 2018 at 12:13 am
Since persistence of antibiotics for a prolonged period in milk triggers antimicrobial resistance (AMR), the polyherbal drug could be used as a supportive therapy to treat sensitive bacterial infectio... […]
ID Journal Club – BLASTing Inappropriate Allergies out of the EMR With Antimicrobial Stewardship
on July 26, 2018 at 7:59 am
Broad spectrum antimicrobial agents also contribute to development of antimicrobial resistance. Evidence supports most patients with reported allergy to a beta-lactam can safely tolerate beta-lactams. ... […]
Countries step up to tackle antimicrobial resistance
on July 18, 2018 at 6:19 am
This puts human and animal health at risk, potentially contributing to the development of antimicrobial resistance. The report highlights areas, particularly in the animal and food sectors, where ther... […]
via Bing News